Fate Therapeutics Stock
Fate Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Bahram Valamehr
- Employees
- 161
- Market cap
- $209 M
- IPO
- 01/10/2013
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and…
Fate Therapeutics stock: price history
1D
-7.3%
1W
-17.9%
1M
-26.6%
6M
+28.8%
YTD
+82.2%
1Y
+16.2%
2Y
-44.2%
5Y
-97.1%
10Y
-29.8%
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~4% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Fate Therapeutics
Analyst assessment of Fate Therapeutics
PRICE TARGET LOW
US$3.50
CONSENSUS
US$5.63
MEDIAN
US$5.50
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
16
BUY
13
HOLD
2
SELL
0
STRONG SELL
31
TOTAL · Buy
As of: 14/08/2026
Fate Therapeutics stock metrics
P/E
-1.7
P/B
1.4
EV/EBITDA
-2.2
RETURN ON EQUITY
-19.7%
NET MARGIN
-1,448.6%
DEBT/EQUITY
0.49
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.5%
FLOAT SHARES
105,482,791
AVG. DAILY VOLUME (30D)
1,454,080
Insider transactions (SEC)
TAHL CINDY
Valamehr Bahram
Valamehr Bahram
TAHL CINDY
TAHL CINDY
Institutional holders
Comparable stocks
Frequently asked questions about Fate Therapeutics stock
What does Fate Therapeutics do?
Fate Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Bahram Valamehr, the company employs around 161 people.
The IPO was on 01/10/2013; the stock trades on NASDAQ under the ticker FATE.
What do analysts say about Fate Therapeutics stock?
31 analysts rate the stock, the consensus is Buy (as of 14/08/2026).
The average price target is US$5.63, ranging from US$3.50 to US$8.00, with a median of US$5.50.
This is an external assessment, not a statement by Market Jury.
When does Fate Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -4% stronger than usual.
Does Fate Therapeutics pay a dividend?
No, Fate Therapeutics currently does not pay a dividend.
Which stocks are comparable to Fate Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Fate Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Fate Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.